Alterity Therapeutics (ATHE) Operating Expenses (2013 - 2025)

Alterity Therapeutics has reported Operating Expenses for 11 years, with the latest figure at -$12.7 million in Q4 2025.

• On a quarterly basis, Operating Expenses fell 46.79% year-over-year to -$12.7 million in Q4 2025; TTM through Dec 2025 was -$43.6 million, a 2.83% decrease from a year earlier, with the FY2026 full-year figure at -$19973.7 billion, down 57.72% from the prior year.
• Operating Expenses was -$12.7 million for Q4 2025 at Alterity Therapeutics, down from -$8.7 million in the prior quarter.
• The five-year high for Operating Expenses was -$8.7 million in Q4 2024, with the low at -$12.7 million in Q4 2025.
• Average Operating Expenses over 5 years is -$11.0 million, with a median of -$11.3 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses gained 20.53% in 2024, then tumbled 46.79% in 2025.
• Over 5 years, Operating Expenses stood at -$11.5 million in 2021, then climbed by 1.96% to -$11.3 million in 2022, then grew by 3.47% to -$10.9 million in 2023, then grew by 20.53% to -$8.7 million in 2024, then sank by 46.79% to -$12.7 million in 2025.
• The last three Operating Expenses figures came in at -$12.7 million (Q4 2025), -$8.7 million (Q4 2024), and -$10.9 million (Q4 2023), per Business Quant data.